Intercept Pharmaceuticals - ICPT Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View ICPT analyst ratings or view top-rated stocks.

9 equities research analysts have issued 1-year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $16.00 to $29.00. On average, they predict the company's share price to reach $22.10 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.

Intercept Pharmaceuticals' stock was trading at $16.29 at the start of the year. Since then, ICPT stock has increased by 2.3% and is now trading at $16.67.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ICPT earnings forecast.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its earnings results on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.15. The biopharmaceutical company earned $100.40 million during the quarter, compared to the consensus estimate of $94.85 million.

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Intercept Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (2.16%), EULAV Asset Management (1.33%), Renaissance Technologies LLC (1.32%), Goldman Sachs Group Inc. (1.23%), Millennium Management LLC (1.12%) and Northern Trust Corp (0.83%). Insiders that own company stock include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends.

Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICPT stock can currently be purchased for approximately $16.67.

Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $496.73 million and generates $363.47 million in revenue each year. The biopharmaceutical company earns $-91,430,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

The company employs 437 workers across the globe.

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.